Back to Gene
PANK2 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

PANK2 gene

The PANK2 gene provides instructions for making the enzyme pantothenate kinase 2, which is vital for the production of coenzyme A within mitochondria.

Normal Function

The PANK2 gene provides instructions for making an enzyme called pantothenate kinase 2. This enzyme is active in specialized cellular structures called mitochondria, which are the cell's energy-producing centers. Within mitochondria, pantothenate kinase 2 regulates the formation of a molecule called coenzyme A. Coenzyme A is found in all living cells, where it is essential for the body's production of energy from carbohydrates, fats, and some protein building blocks (amino acids).

PANK2 is one of four human genes that provide instructions for making versions of pantothenate kinase. The functions of these different versions probably vary among tissue types and parts of the cell. The version produced by the PANK2 gene is active in cells throughout the body, including nerve cells in the brain.

Health Conditions Related to Genetic Changes

Pantothenate kinase-associated neurodegeneration

About 100 mutations in the PANK2 gene have been identified in people with pantothenate kinase-associated neurodegeneration. Typically, people with the more severe, early-onset form of the disorder have PANK2 mutations that prevent cells from producing any functional pantothenate kinase 2. People affected by the atypical, later-onset form usually have mutations that change single amino acids in the enzyme, which makes the enzyme unstable or disrupts its activity. In some cases, single amino acid changes allow the enzyme to retain some function. The most common PANK2 mutation replaces the amino acid glycine with the amino acid arginine at position 411 of the enzyme (written as Gly411Arg or G411R).

When pantothenate kinase 2 is altered or missing, the normal production of coenzyme A is disrupted and potentially harmful compounds can build up in the brain. This buildup leads to swelling, tissue damage, and an abnormal accumulation of iron in certain areas of the brain. Researchers are uncertain how a lack of functional pantothenate kinase 2 causes the specific features of pantothenate kinase-associated neurodegeneration. Because the enzyme functions in mitochondria, the signs and symptoms of this condition may be related to impaired energy production.

Mutations in the PANK2 gene are also found in people with a condition called HARP (hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration). HARP was historically described as a separate syndrome but is now considered part of pantothenate kinase-associated neurodegeneration. Although HARP is much rarer than classic pantothenate kinase-associated neurodegeneration, both conditions involve problems with movement, dementia, and vision abnormalities.

Frequently Asked Questions

PKAN is inherited in an autosomal recessive manner. Both parents are typically carriers, and each sibling has a 25 % chance of being affected, a 50 % chance of being a carrier, and a 25 % chance of being unaffected and not a carrier. Carrier testing for at‑risk relatives and prenatal or pre‑implantation genetic testing are options. A certified genetic counselor can explain risks, testing options, and family planning implications.
No cure exists, but symptomatic therapies can help. Iron‑chelation agents (e.g., deferiprone) have been studied to reduce brain iron accumulation, with mixed results. Medications such as baclofen, trihexyphenidyl, or botulinum toxin can alleviate dystonia. Physical, occupational, and speech therapy are essential for maintaining function. Clinical trials of gene therapy and enzyme replacement are ongoing.
Early signs often appear before age 10 and include progressive dystonia (involuntary muscle contractions), rigidity, difficulty walking, speech changes, and a characteristic “eye‑of‑the‑tiger” sign on brain MRI (central hyperintensity surrounded by hypointensity in the globus pallidus). Early motor regression, swallowing difficulties, and pigmentary retinopathy can also be clues.
The classic early‑onset form typically progresses rapidly, with loss of ambulation within a few years and increasing dependence on caregivers. Life expectancy varies; many patients survive into adulthood but may develop complications such as aspiration pneumonia or severe rigidity that can affect survival. Regular multidisciplinary care can improve quality of life and manage complications.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA